Gately S - Search Results

Year	Number of Results
1990	1
1991	1
1992	1
1994	3
1995	3
1996	1
1997	3
1998	2
1999	1
2000	1
2001	1
2002	1
2003	1
2004	1
2005	1
2011	2
2012	2
2013	1
2014	1
2015	1
2019	2
2022	1
2024	0

1

Female with left-sided numbness and weakness.

Gately SC, Smereck JA, Davis JE. Gately SC, et al. J Am Coll Emerg Physicians Open. 2022 Feb 28;3(2):e12665. doi: 10.1002/emp2.12665. eCollection 2022 Apr. J Am Coll Emerg Physicians Open. 2022. PMID: 35252970 Free PMC article. No abstract available.

2

The contributions of cyclooxygenase-2 to tumor angiogenesis.

Gately S. Gately S. Cancer Metastasis Rev. 2000;19(1-2):19-27. doi: 10.1023/a:1026575610124. Cancer Metastasis Rev. 2000. PMID: 11191059 Review.

3

Synthesis of improved lysomotropic autophagy inhibitors.

Wang T, Goodall ML, Gonzales P, Sepulveda M, Martin KR, Gately S, MacKeigan JP. Wang T, et al. Among authors: gately s. J Med Chem. 2015 Apr 9;58(7):3025-35. doi: 10.1021/jm501586m. Epub 2015 Mar 27. J Med Chem. 2015. PMID: 25793774

4

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

Gately S, Li WW. Gately S, et al. Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11. doi: 10.1053/j.seminoncol.2004.03.040. Semin Oncol. 2004. PMID: 15179620 Review.

5

β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.

Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I, Dunckley T. Frost D, et al. Among authors: gately s. PLoS One. 2011 May 6;6(5):e19264. doi: 10.1371/journal.pone.0019264. PLoS One. 2011. PMID: 21573099 Free PMC article.

6

A diaminoantraquinone inhibitor of angiogenesis.

Takano S, Gately S, Jiang JB, Brem S. Takano S, et al. Among authors: gately s. J Pharmacol Exp Ther. 1994 Nov;271(2):1027-33. J Pharmacol Exp Ther. 1994. PMID: 7525934

7

Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.

Gately S, Kerbel R. Gately S, et al. Prog Exp Tumor Res. 2003;37:179-92. doi: 10.1159/000071373. Prog Exp Tumor Res. 2003. PMID: 12795055 Review.

8

Antiangiogenic scheduling of lower dose cancer chemotherapy.

Gately S, Kerbel R. Gately S, et al. Cancer J. 2001 Sep-Oct;7(5):427-36. Cancer J. 2001. PMID: 11693902 Review.

9

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. Gately S, et al. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10868-72. doi: 10.1073/pnas.94.20.10868. Proc Natl Acad Sci U S A. 1997. PMID: 9380726 Free PMC article.

10

Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.

Demeure MJ, Stephan E, Sinari S, Mount D, Gately S, Gonzales P, Hostetter G, Komorowski R, Kiefer J, Grant CS, Han H, Von Hoff DD, Bussey KJ. Demeure MJ, et al. Among authors: gately s. Ann Surg. 2012 Jan;255(1):140-6. doi: 10.1097/SLA.0b013e3182402d21. Ann Surg. 2012. PMID: 22156929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

32 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year